4baseCare combines genomics and AI to deliver personalized cancer treatment plans based on patient genetic and clinical data.
$0Series B
A $0M Series B is either a data error or a bridge round—either way, it signals growX is backing the precision oncology thesis in India, where genomics infrastructure is still nascent but labor costs make the unit economics work. If you're building in adjacent diagnostic verticals (rare disease, pharmacogenomics), watch whether 4baseCare can actually move the needle on treatment outcomes; that's the moat that matters, not just the AI wrapper.